Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start.

ABSTRACT:

SUBMITTER: Facchinetti F 

PROVIDER: S-EPMC5943229 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature